当前位置:循环首页>正文

[CIT2010]我们可以从动物研究和实验研究中学到什么?—Roxana Mehran教授专访

作者:国际循环网   日期:2010/3/31 19:08:00

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

I think it is really important and essential that when you are looking at the results of a clinical trial to see how it was designed, the hypotheses that were generated, the assumptions that were made, and the statistical analysis plan as well as the conduct of the trial itself. We need to look at whether it was multi-centered, randomized......

    <International Circulation>: Bivalirudin has been included as a class-one recommendation as an anticoagulant therapy for primary PCI.  Do you have a view on this change?
 
    Roxana Mehran:Of course I do, because I conducted the HORIZONS AMI study and I think that was the one trial where we showed that by having a drug that was associated with less bleeding we actually saved lives and we did not have to pay any tax  on ischemic complications, so I think that is a fantastic choice.  The one piece we have to work out is the stent thrombosis.  Prasugrel seems to be the right fit, but it needs to be studied in order to say that it should be applied, across the board, to all STEMI patients.

上一页  [1]  [2]  [3]  [4]  

版面编辑:沈会会



Roxana Mehran

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530